Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings

A Correction to this article was published on 03 June 2020

This article has been updated


Many hypothesis suggest that inflammation plays an important role in schizophrenia. Galectins can regulate inflammatory response in central nervous system. The relation between galectins and neuropsyhchiatric diseases and schizophrenia is unclear. The present study compared levels of Gal-1 and Gal-3 of patients with schizophrenia to that of first-degree relatives without the disease and healthy controls in order to evaluate any possible association. Sixty-two patients with schizophrenia, fifty-five unaffected siblings and fifty-eight age- and sex-matched healthy controls enrolled. Serum Gal-1, Gal-3 and CRP levels were measured. PANNS and CGI-S were used to evaluate the severity of disease. There was a statistically significant difference in serum Gal-1 levels among the patient, sibling, and control groups. There were no statistically significant correlations between serum CRP ​​and serum Gal-1 or Gal-3 levels. Gal-1 values were significantly higher in the unaffected siblings compared to both the patient group and the healthy control group. Gal-3 levels were elevated in the sibling group relative to the patient group. In the literature, the relationship between galectins and schizophrenia is very limited and appears to be a new field of study. Future studies are needed to evaluate the protective roles of galectins.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Change history

  • 03 June 2020

    The original version of this article unfortunately contained a mistake. The name of the 5th author was incorrectly listed as Çiğdem Yüksel, when it is actually Çiğdem Yücel. The correct information is as shown above.


  1. 1.

    Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, et al. Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol. 2006;168:1910–20.

    CAS  Article  Google Scholar 

  2. 2.

    Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93:23–58.

    CAS  Article  Google Scholar 

  3. 3.

    Chen HL, Liao F, Lin TN, Liu FT. Galectins and neuroinflammation. Springer, New York: In glycobiology of the nervous system; 2014. p. 517–42.

    Google Scholar 

  4. 4.

    Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker P, Poirier F. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology. 1998;94:290–6.

    CAS  Article  Google Scholar 

  5. 5.

    Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261–5.

    Article  Google Scholar 

  6. 6.

    Dong H, Wang Z-H, Zhang N, Liu SD, Zhao JJ, Liu SY (2017) Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke. Oncotarget8:109752.

  7. 7.

    Egnaczyk GF, Pomonis JD, Schmidt JA, Rogers SD, Peters C, Ghilardi JR, et al. Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics. 2003;3:689–98.

    CAS  Article  Google Scholar 

  8. 8.

    Elola M, Wolfenstein-Todel C, Troncoso M, Vasta G, Rabinovich G. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64:1679–700.

    CAS  Article  Google Scholar 

  9. 9.

    Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7.

    Article  Google Scholar 

  10. 10.

    He J, Baum LG. Galectin interactions with extracellular matrix and effects on cellular function. Methods Enzymol. 2006;417:247–56.

    CAS  Article  Google Scholar 

  11. 11.

    Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung W-P, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156:1073–83.

    CAS  Article  Google Scholar 

  12. 12.

    Hsuchou H, Kastin AJ, Mishra PK, Pan W (2012) C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem30:1109–1119.

  13. 13.

    Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Nakataki M, et al. A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep. 2016;6:26105.

    CAS  Article  Google Scholar 

  14. 14.

    Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168:456–60.

    Article  Google Scholar 

  15. 15.

    Kajitani K, Yanagimoto K, Nakabeppu Y. Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation. Psychopharmacology. 2017;234:2919–27.

    CAS  Article  Google Scholar 

  16. 16.

    Kaltner H, Seyrek K, Heck A, Sinowatz F, Gabius HJ. Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Cell Tissue Res. 2002;307:35–46.

    CAS  Article  Google Scholar 

  17. 17.

    Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174–9.

    Article  Google Scholar 

  18. 18.

    Kuhlmann CR, Librizzi L, Closhen D, Pflanzner T, Lessmann V, Pietrzik CU, et al. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke. 2009;40:1458.

    CAS  Article  Google Scholar 

  19. 19.

    Lai C-Y, Scarr E, Udawela M, Everall I, Chen WJ, Dean B (2016) Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. World J Psychiatry6:102.

  20. 20.

    Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29.

    CAS  Article  Google Scholar 

  21. 21.

    Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR, et al. Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol. 2012;132:2828–37.

    CAS  Article  Google Scholar 

  22. 22.

    Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66:1–11.

    CAS  Article  Google Scholar 

  23. 23.

    McGraw J, Gaudet A, Oschipok L, Kadoya T, Horie H, Steeves J, Tetzlaff W, Ramer M (2005) Regulation of neuronal and glial galectin-1 expression by peripheral and central axotomy of rat primary afferent neurons. Exp Neurol195:103–114.

  24. 24.

    Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry70:663–671.

  25. 25.

    Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses7:223–230.

  26. 26.

    Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia: an integrative view. Ann N Y Acad Sci. 2000;917:456–67.

    Article  Google Scholar 

  27. 27.

    Nonaka M, Fukuda M. Galectin-1 for neuroprotection? Immunity. 2012;37:187–9.

    CAS  Article  Google Scholar 

  28. 28.

    Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002;23:313–20.

    CAS  Article  Google Scholar 

  29. 29.

    Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS (2003) Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc35:1160–1166.

  30. 30.

    Richard MD, Bram NC (2012) Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm69:757–766.

  31. 31.

    Shin T (2013) The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochemica1 15:407-411.

  32. 32.

    Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 2014;216:277–85.

    CAS  Article  Google Scholar 

  33. 33.

    Sirko S, Irmler M, Gascón S, Bek S, Schneider S, Dimou L, et al. Astrocyte reactivity after brain injury: the role of galectins 1 and 3. Glia. 2015;63:2340–61.

    Article  Google Scholar 

  34. 34.

    Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012;37:249–63.

    CAS  Article  Google Scholar 

  35. 35.

    Tandon R, Keshavan MS, Nasrallah HA (2008) Schizophrenia,“just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102:1–18, Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.

  36. 36.

    Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A, et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes. 2011;35:300.

    CAS  Article  Google Scholar 

  37. 37.

    Venkatraman A, Hardas S, Patel N, Singh Bajaj N, Arora G, Arora P. Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol. 2018;25:238–46.

    CAS  Article  Google Scholar 

  38. 38.

    Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.

    CAS  Article  Google Scholar 

  39. 39.

    Wada M, Ono S, Kadoya T, Kawanami T, Kurita K, Kato T. Decreased galectin-1 immunoreactivity of the skin in amyotrophic lateral sclerosis. J Neurol Sci. 2003;208:67–70.

    CAS  Article  Google Scholar 

  40. 40.

    Wang X, Zhang S, Lin F, Chu W, Yue S. Elevated galectin-3 levels in the serum of patients with Alzheimer's disease. Am J Alzheimers Dis Other Dement. 2015;30:729–32.

    Article  Google Scholar 

  41. 41.

    Wang Z, Li P, Chi D, Wu T, Mei Z, Cui G. Association between C-reactive protein and risk of schizophrenia: an updated meta-analysis. Oncotarget. 2017;8:75445.

    Article  Google Scholar 

  42. 42.

    Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Medicine. 2011;123:114–9.

    Article  Google Scholar 

  43. 43.

    Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem. 2006;78:3571–6.

    CAS  Article  Google Scholar 

  44. 44.

    Yip PK, Carrillo-Jimenez A, King P, Vilalta A, Nomura K, Chau CC, et al. Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. Sci Rep. 2017;7:41689.

    CAS  Article  Google Scholar 

  45. 45.

    Yüksel RN, Ertek IE, Dikmen AU, Göka E. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters. Nord Journal Psychiat. 2018;72:336–40.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Rabia Nazik Yüksel.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

Declaration of Interest

No potential conflict of interest was reported by the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: The spelling of the family name of the fifth author was corrected.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yüksel, R.N., Göverti, D., Kahve, A.C. et al. Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings. Psychiatr Q 91, 715–725 (2020).

Download citation


  • Galectins
  • Schizophrenia
  • Galectin 1
  • Galectin 3
  • CRP
  • Psychosis